Abortifacient Drugs

  • M. Bygdeman


Interruption of pregnancy applies to gravidae at less than 28 full weeks’ gestation with a quiescent uterus. Practically, in the overwhelming majority of cases, abortion should be performed prior to viability or at less than 22 weeks’ gestation.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Amy, J. J., Thiery, M., Bygdeman, M., Kerenyi, T. D., Crawford, J. S. and Karim, S. M. M. (1976). A suggested set of working definitions and criteria applicable to interruption of pregnancy. Contraception, 14, 193–7CrossRefPubMedGoogle Scholar
  2. Baulieu, E. E. (1985). RU 486: An antiprogestin steroid with contragestive activity in women. In Baulieu, E. E. and Segal, S. J. (Eds.), The Antiprogestin Steroid RU 486 and Human Fertility Controls. Plenum Press, New York, pp. 1–25CrossRefGoogle Scholar
  3. Brenner, W. E. (1972). Second trimester interruption of pregnancy. In Taymor, M. K. and Green T. H. (Eds.), Progress in Gynecology, Vol. 6. Grune and Stratton, New York, pp. 421–44Google Scholar
  4. Brenner, W. E. (1975). The current status of prostaglandins as abortifacients. Am. J. Obstet. Gynecol., 123, 306–28PubMedGoogle Scholar
  5. Bygdeman, M. (1978). Comparison of prostaglandin and hypertonic saline for termination of pregnancy. Obstet. Gynecol., 52, 424–9PubMedGoogle Scholar
  6. Bygdeman, M. (1984). The use of prostaglandins and their analogues for abortion. In Newton, J. R. (Ed.), Clinics in Obstetrics and Gynaecology, Vol. 11. W. B. Saunders, London, pp. 573–84Google Scholar
  7. Bygdeman, M., Borell, U., Leader, A., Lundström, V., Martin, J. N., Jr., Eneroth, P. and Gréen, K. (1976). Induction of first and second trimester abortion by the vaginal administration of 15-methyl PGF methyl ester. In Samuelsson, B. and Paoletti, R. (Eds.), Advances in Prostaglandin and Thromboxane Research, Vol. 2. Raven Press, New York, pp. 693–704Google Scholar
  8. Bygdeman, M., Christensen, N. J., Gréen, K. and Vesterqvist, O. (1984). Seifadministration at home of prostaglandin for termination of early pregnancy. In Toppozada, M., Bygdeman, M. and Hafez, E. S. E. (Eds.), Prostaglandins and Fertility Regulation. MTP, Lancaster, pp. 83–90CrossRefGoogle Scholar
  9. Bygdeman, M. and Swahn, M. L. (1985). Progesterone receptor blockage. Effect on uterine contractility in early pregnancy. Contraception, 32, 45–51CrossRefPubMedGoogle Scholar
  10. Bygdeman, M. and Van Look, P. F. A. (1988). Antiprogestins for the interruption of pregnancy. In Healy, D. L. (Ed.), Ballière’s Clinical Obstetrics and Gynaecology. Anti-hormones in Clinical Gynaecology. Ballière Tindall, London, pp. 617–29Google Scholar
  11. Christensen, N. J., Belfrage, P., Bygdeman, M., Floberg, J., Mitzuhashi, N. and Gréen, K. (1985). Bioconversion of arachidonic acid in human pregnant uterine cervix. Acta Obstet. Gynecol. Scand., 64, 259–65CrossRefPubMedGoogle Scholar
  12. Chwalisz, K., Qing, S. S., Neef, G. and Elger, W. (1987). The effect of the antigestagen ZK 98,299 on the uterine cervix. Acta Endocrinol., 283 (Suppl.), 113–14Google Scholar
  13. Edelman, D. A., Brenner, W. E. and Berger, G. B. (1974). Effectiveness and complication of abortion by dilatation and vacuum aspiration versus dilatation and rigid metal curettage. Am. J. Obstet. Gynecol., 119, 473–80PubMedGoogle Scholar
  14. Galen, R. S., Chauhan, P., Wietzner, H. and Navarro, C. (1974). Fetal pathology and mechanism of fetal death in saline induced abortion: a study of 143 gestations and critical review of the literature. Am. J. Obstet. Gynecol., 12, 347–55Google Scholar
  15. Gréen, K., Bygdeman, M. and Wiqvist, N. (1974). Kinetic and metabolic studies of prostaglandin F administered intra-amniotically for induction of abortion. Life Sci., 14, 2285–97CrossRefPubMedGoogle Scholar
  16. Gréen, K., Christensen, N. and Bygdeman, M. (1981). The chemistry and pharmacology of prostaglandins with reference to human reproduction. J. Reprod. Fertil., 62, 269–81CrossRefPubMedGoogle Scholar
  17. Gréen, K., Granström, E., Bygdeman, M. and Wiqvist, N. (1976). Kinetic and mrtabolic studies of 15-methyl PF administered intra-amniotically for induction of abortion. Prostaglandins, 11, 699–711CrossRefPubMedGoogle Scholar
  18. Gustavii, B. and Gréen, K. (1972). Release of prostaglandin F following injection of hypertonic saline for therapeutic abortion. A preliminary study. Am. J. Obstet. Gynecol., 114, 1099–100PubMedGoogle Scholar
  19. Hulka, J. F., Leffler, H. T., Jr., Anglone, A. and Lachenbruch, P. A. (1974). A new electronic force monitor to measure factors influencing cervical dilatation for vacuum curettage. Am. J. Obstet. Gynecol., 120, 166–73PubMedGoogle Scholar
  20. Kelly, R. W., Healy, D. L., Cameron, I. and Baird, D. T. (1986). The stimulation of prostaglandin production by two antiprogesterone steroids in human endometrial cells. J. Clin. Endocrinol. Metab., 62, 1117–23Google Scholar
  21. Kerenyi, T. D. (1972). Technique of late abortion. In Lewit, S. (Ed.), Abortion Techniques and Services. Excerpta Medica, Amsterdam, pp. 17–22Google Scholar
  22. Mandelin, M. (1978). Termination of early pregnancy by a single dose 3.0 mg 15-methyl PGF methyl ester vaginal suppository. Prostaglandins, 16, 143–51CrossRefPubMedGoogle Scholar
  23. Newton, J., Barnard, G. and Collons, W. (1977). A rapid method for measuring blood loss using autonomic extraction. Contraception, 16, 269–82CrossRefGoogle Scholar
  24. Ölund, A. (1978). The effect of indomethacin on the instillation-abortion interval in Rivanol-induced mid-trimester abortion. Acta Obstet. Gynecol. Scand., 57, 333–6CrossRefPubMedGoogle Scholar
  25. Ott, E. R. (1977). Cervical dilatation—A review. Population Reports, Series F, No. 6Google Scholar
  26. Rådestad, A., Christensen, N. J. and Strömberg, L. (1988). Cervical ripening with Mifepristone in first trimester abortion. A double-blind randomized biomechanical study. Contraception, 38, 301–12CrossRefPubMedGoogle Scholar
  27. Rodger, M. W. and Baird, D. T. (1987). Induction of therapeutic abortion in early pregnancy with mifepristone in combination with prostaglandin pessary. Lancet, ii, 1415–18CrossRefGoogle Scholar
  28. Rooks, J. B. and Cates, W., Jr. (1977). Emotional impact of D&E vs. instillation. Fam. Plann. Perspect., 9, 276–7CrossRefPubMedGoogle Scholar
  29. Rosén, A.-S., Nystedt, L., Bygdeman, M. and Lundström, V. (1979). Acceptability of a non-surgical method to terminate very early pregnancy in comparison to vacuum aspiration. Contraception, 19, 107–17CrossRefPubMedGoogle Scholar
  30. Rosén, A.-S., von Knorring, K., Bygdeman, M. and Christensen, N. (1984). Randomized comparison of prostaglandin treatment in hospital or at home with vacuum aspiration for termination of early pregnancy. Contraception, 29, 423–35CrossRefPubMedGoogle Scholar
  31. Swahn, M. L. and Bygdeman, M. (1988). The effect of the antiprogestin RU 486 on uterine contractility and sensitivity to prostaglandin and oxytocin. Br. J. Obstet. Gynaecol., 95, 126–34CrossRefPubMedGoogle Scholar
  32. Swahn, M. L., Ugocsai, G., Bygdeman, M., Kovacs, L., Belsey, E. M. and Van Look, P. F. A. (1989). Effect of oral prostaglandins E2 on uterine contractility and treatment outcome in women receiving RU 486 (mifepristone) for termination of early pregnancy. Hum. Reprod., 4, 21PubMedGoogle Scholar
  33. Tietze, C. and Henshaw, S. K. (1986). Induced Abortion: A World Review 1986. Alan Guttmacher Institute, New York and WashingtonGoogle Scholar
  34. Tietze, C. and Lewit, S. (1972). Joint program for the study of gestation (JPSA). Early medical complications of legal abortion. Stud. Fam. Plann., 3, 97CrossRefGoogle Scholar
  35. Toppozada, M., Beguin, F., Bygdeman, M. and Wiqvist, N. (1972). Response of the midpregnant human uterus to systemic administration of 15(S)15-methyl prostaglandin F. Prostaglandins, 2, 239–49CrossRefPubMedGoogle Scholar
  36. Uldbjerg, N., Ulmsten, U. and Ekman, G. (1987). The physiological role of eicosanoids in controlling the form and function of the cervix. In Hillier, K. (Ed.), Advances in Eicosanoid Research. MTP, Lancaster, pp. 163–83CrossRefGoogle Scholar
  37. Waltman, R., Tricorni, V. and Palay, A. (1973). Aspirin and indomethacin: Effect on instillation/abortion time of mid-trimester hypertonic saline induced abortion. Prostaglandins, 3, 47–58CrossRefPubMedGoogle Scholar
  38. Van Look, P. F. A. (1989). Antiprogestin: a new era in hormonal regulation of fertility. In Proceedings of the First Congress of the International Society of Gynecological Endocrinology. Parthenon Publishing, Carnforth (in press)Google Scholar
  39. WHO Task Force on Post-ovulatory Methods for Fertility Regulation (1987). Menstrual regulation by intramuscular injection of 16-phenoxy-tetranor PGE2 methyl sulfonylamide or vacuum aspiration. A randomized multicenter study. Br. J. Obstet. Gynaecol., 94, 949–56CrossRefGoogle Scholar
  40. Zuspan, F. P., Ballard, C. A., Bieniarz, J., Brenner, W. E., Corson, S. L., Kaiser, I. H., Kerenyi, T. D., King, T. M. and Tietze, C. (1976). Second trimester abortion—a symposium by correspondence. J. Reprod. Med., 16 (2), 47–64PubMedGoogle Scholar

Copyright information

© The editors and contributors 1990

Authors and Affiliations

  • M. Bygdeman
    • 1
  1. 1.Dept of Obstetrics and GynaecologyKarolinska HospitalStockholmSweden

Personalised recommendations